:STATS

:PROFILE
Orforglipron
subtitle: Eli Lilly's oral GLP-1 receptor agonist
Orforglipron (LY3502970) is a small-molecule GLP-1 receptor agonist taken once daily as a tablet. Un

:CHECKLIST
subtitle: What the three Phase 3 trials showed
[ ] ATTAIN-1 (no diabetes): highest dose lost 12.4% body weight vs placebo at 72 weeks
[ ] ATTAIN-1: nearly 1 in 5 participants shed 20% or more of total body weight
[ ] ATTAIN-2 (with type 2 diabetes): 10.5% weight loss, A1C cut by 1.3 to 1.8 percentage points
[ ] ATTAIN-2: 75% on highest dose reached A1C at or below 6.5%, the ADA's diabetes threshold
[ ] ACHIEVE-3: orforglipron beat oral semaglutide (both 7 mg and 14 mg doses) on all key endpoints
[ ] ACHIEVE-3: greater A1C reduction AND greater weight loss than best available oral GLP-1
[ ] Safety profile consistent with injectable GLP-1 class (nausea, vomiting most common)
[ ] No food or fasting window required, unlike oral semaglutide which demands 30-minute fast

:NOTE
Why no fasting requirement matters. Oral semaglutide (Rybelsus, same active ingredient as Ozempic) requires patients to swallow it on an empty stomach and then wait 30 minutes before eating or drinking anything other than water. That window is a compliance barrier in real life. Orforglipron is a different molecular class altogether, a small molecule rather than a peptide, which is why it is absorbed without that restriction. A pill you can take with breakfast is meaningfully easier to sustain.


:NOTE
The existing injectable GLP-1 landscape for context. Semaglutide (Wegovy) injected weekly achieves roughly 15% body weight loss. Tirzepatide (Zepbound), the dual GIP/GLP-1 agonist, reaches about 21% in its highest-dose Phase 3 data. Orforglipron's 12.4% figure (without diabetes) is below tirzepatide but firmly in the clinically meaningful range, and critically, it is an oral tablet, not a weekly injection. Access, cost, and adherence could be transformed if it clears regulatory review.


:NOTE
Regulatory timeline. Eli Lilly expects to submit orforglipron for weight management to global regulators by end of 2025, with the type 2 diabetes submission following in 2026. Assuming a standard 12-month FDA review, a US approval for obesity could arrive in late 2026 or early 2027. The European Medicines Agency review would run roughly parallel. Lilly has not yet announced pricing.


:LINK
https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-delivered-superior-blood-sugar
Eli Lilly ACHIEVE-3 results: orforglipron vs oral semaglutide, The Lancet (July 2026)
|
:LINK
https://www.sciencedaily.com/releases/2026/07/260707054111.htm
New weight loss pill beats oral Ozempic in major trial (ScienceDaily, July 7 2026)
|
:LINK
https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-meaningful-weight
Eli Lilly ATTAIN-1 results: NEJM publication (72-week obesity trial)